323 related articles for article (PubMed ID: 26631176)
1. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.
Haque R; Shi J; Schottinger JE; Ahmed SA; Cheetham TC; Chung J; Avila C; Kleinman K; Habel LA; Fletcher SW; Kwan ML
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26631176
[TBL] [Abstract][Full Text] [Related]
2. Use of antidepressants and breast cancer recurrence.
Baker H
Lancet Oncol; 2016 Jan; 17(1):e11. PubMed ID: 26687592
[No Abstract] [Full Text] [Related]
3. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.
Kelly CM; Juurlink DN; Gomes T; Duong-Hua M; Pritchard KI; Austin PC; Paszat LF
BMJ; 2010 Feb; 340():c693. PubMed ID: 20142325
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer recurrence in relation to antidepressant use.
Chubak J; Bowles EJ; Yu O; Buist DS; Fujii M; Boudreau DM
Cancer Causes Control; 2016 Jan; 27(1):125-36. PubMed ID: 26518198
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT; Pedersen L
Acta Oncol; 2010 Apr; 49(3):305-12. PubMed ID: 20156115
[TBL] [Abstract][Full Text] [Related]
6. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
Lash TL; Gurwitz JH; Silliman RA
J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
[TBL] [Abstract][Full Text] [Related]
7. [Patient safety with breast cancer and depression: Concomitant use of paroxetine and tamoxifen].
Muquebil Ali Al Shaban Rodríguez OW; Pérez Castro P; Estrada Alarcón N; Tuñón Gorgojo L
J Healthc Qual Res; 2019; 34(2):110-111. PubMed ID: 30686622
[No Abstract] [Full Text] [Related]
8. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.
Dignam JJ; Wieand K; Johnson KA; Fisher B; Xu L; Mamounas EP
J Natl Cancer Inst; 2003 Oct; 95(19):1467-76. PubMed ID: 14519753
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen.
Kwan ML; Shi JM; Habel LA; Song J; Chung JW; Avila CC; Schottinger JE; Cheetham TC; Fletcher SW; Haque R
Breast Cancer Res Treat; 2016 Apr; 156(2):379-89. PubMed ID: 27002508
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
Lash TL; Pedersen L; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT
Br J Cancer; 2008 Aug; 99(4):616-21. PubMed ID: 18665165
[TBL] [Abstract][Full Text] [Related]
11. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study.
Guha N; Kwan ML; Quesenberry CP; Weltzien EK; Castillo AL; Caan BJ
Breast Cancer Res Treat; 2009 Nov; 118(2):395-405. PubMed ID: 19221874
[TBL] [Abstract][Full Text] [Related]
12. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
13. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.
Dusetzina SB; Alexander GC; Freedman RA; Huskamp HA; Keating NL
Breast Cancer Res Treat; 2013 Jan; 137(1):285-96. PubMed ID: 23149465
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
15. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer.
Nekhlyudov L; Li L; Ross-Degnan D; Wagner AK
Breast Cancer Res Treat; 2011 Nov; 130(2):681-9. PubMed ID: 21842245
[TBL] [Abstract][Full Text] [Related]
16. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of tamoxifen reduces the risk of dementia: a nationwide population-based cohort study.
Sun LM; Chen HJ; Liang JA; Kao CH
QJM; 2016 Feb; 109(2):103-9. PubMed ID: 25852154
[TBL] [Abstract][Full Text] [Related]
18. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
[TBL] [Abstract][Full Text] [Related]
19. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study.
Tzeng HE; Muo CH; Chen HT; Hwang WL; Hsu HC; Tsai CH
BMC Musculoskelet Disord; 2015 May; 16():123. PubMed ID: 25989902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
